Thomas F. Lüscher/LinkedIn
Aug 5, 2026, 14:25
Thomas F. Lüscher: ZEUS Trial Highlights the Challenge of Translating Anti-Inflammatory Effects into Clinical Benefit
Thomas F. Lüscher, Director of Research, Education and Development and Consultant of Cardiology at Royal Brompton and Harefield Hospitals, shared a post on LinkedIn:
“ZEUS has been angry: Ziltivekimab reduced IL-6 and hsCRP, but did not translate into MACE risk reduction versus placebo in patients with ASCVD, CKD and inflammation (HR 0.99; CI 0.88-1.11) – will Artemis (AMI) and Hermes (HfpEF) be in better mood?
It is important to continue with these trials as CKD patients may be different, too late in the course of CVD to make a difference with IL-6 blockade.”
Stay updated with Hemostasis Today.
-
Sep 21, 2026, 13:21In His Last UNGA, António Guterres Delivers a Urgent Call for Global Unity
-
Sep 21, 2026, 13:14Fatih Mehmet Gul: Are We Moving Faster Than Our Ability to Ask ‘Should We?’
-
Sep 21, 2026, 13:08Sangita Reddy: How Does Our Own Healthcare Journey in India Look Through the Same Lens?
-
Sep 21, 2026, 12:53Conan McIlwrath: Strengthening Haemophilia Care Through International Collaboration
-
Sep 21, 2026, 12:41Tinatin Muradashvili: Advancing Hemophilia Care Through Education and Collaboration
-
Sep 21, 2026, 12:15Kholoud Al Busaidi: Cold Agglutination and Its Impact on CBC and Blood Grouping Results
-
Sep 21, 2026, 11:03Shaurav Bhattacharyya: Honoring the 2026 Lasker Award Winners
-
Sep 21, 2026, 10:41Jamshid Ullah: Recognizing Blood Disorders Through Laboratory Findings
-
Sep 21, 2026, 10:18Mana Alshehri: A New Step Toward Hemophilia B Gene Therapy in Adolescents